Innovative Findings from Rhythm Pharmaceuticals at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –
- Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s -
BOSTON — Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), a pioneering biopharmaceutical company dedicated to improving the lives of individuals with rare neuroendocrine conditions, recently showcased vital data on their clinical programs for acquired hypothalamic obesity at the Endocrine Society’s Annual Meeting (ENDO 2025).
Acquired hypothalamic obesity is a critical health issue triggered by damage to the hypothalamic region of the brain, often due to brain tumors. This condition can lead to severe complications such as rapid weight gain and ineffective regulation of appetite and energy expenditure.
Highlighting Bivamelagon's Efficacy
Effectiveness and Safety of Bivamelagon: Insights from the Phase 2 SIGNAL Trial
This data, presented by Dr. Vidhu Thaker from Columbia University, revealed promising results from the Phase 2 trial assessing bivamelagon, an oral and selective MC4R agonist. Notably, the analysis demonstrated significant reductions in body mass index (BMI) over 14 weeks:
- - A decrease of 9.3% in the BMI of patients taking 600mg (n=8);
- - A drop of 7.7% in patients taking 400mg (n=7);
- - A reduction of 2.7% in the 200mg cohort (n=6);
- - In contrast, the placebo group (n=7) experienced an increase of 2.2% in BMI.
Dr. Thaker emphasized the significance of these findings, calling attention to the burden that acquired hypothalamic obesity puts on patients and the transformative potential of therapies like bivamelagon.
Setmelanotide's Promising Outcomes
Results from the Phase 3 TRANSCEND Trial
Dr. Susan Phillips from the University of California San Diego elaborated on the findings from the largest placebo-controlled trial in this area, emphasizing how setmelanotide stands out:
- - A noteworthy 19.8% placebo-adjusted difference in BMI reduction (N=120);
- Significant reductions were consistently noted across different age and sex groups, showing varying decreases between 15.6% and 17.2% in BMI;
- Enhancements in BMI markers for participants with prior or concurrent GLP-1 use were significant, with a mean reduction from baseline of -19.3% for those with previous GLP-1 exposure compared to +5.4% for placebo, and -25.1% for those using GLP-1 alongside setmelanotide.
- For participants under 18, setmelanotide produced a remarkable -26.2% change in BMI at week 52.
Dr. Phillips remarked on the trial's capacity to shift the treatment landscape for acquired hypothalamic obesity, stressing the impressive nearly 20% placebo-adjusted BMI reduction, underlining the potential to aid both children and adults.
Patient Perspectives on Acquired Hypothalamic Obesity
Insights from Exit Interviews
On July 14, Dr. Christian Roth from Seattle Children’s Research Institute presented qualitative feedback from patients affected by this condition, showcasing the human side of clinical trials and underscoring the real-world implications of acquired hypothalamic obesity.
Given the profound impact of acquired hypothalamic obesity, Rhythm Pharmaceuticals counts around 5,000 to 10,000 individuals affected in the United States alone. These statistics highlight the critical need for effective therapeutic options.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals specializes in handling rare neuroendocrine diseases, boasting its flagship treatment, IMCIVREE® (setmelanotide). This drug has secured FDA approval for managing obesity linked to specific genetic conditions. Both the European Commission and the UK’s Medicines & Healthcare Products Regulatory Agency have also recognized setmelanotide's efficacy for related obesity management.
Frequently Asked Questions
What is acquired hypothalamic obesity?
Acquired hypothalamic obesity is a rare form of obesity that occurs due to damage to the hypothalamic area of the brain, disrupting hunger signals and energy balance.
What are MC4R agonists?
MC4R agonists are compounds that target the melanocortin-4 receptor, which plays a crucial role in regulating appetite and energy expenditure, thus potentially aiding in weight management.
What role does setmelanotide play in treatment?
Setmelanotide is aimed at managing obesity related to specific syndromic or genetic conditions and has shown promising efficacy in clinical trials.
What is the significance of the ENDO 2025 presentations?
The presentations deliver crucial insights and data supporting the efficacy of bivamelagon and setmelanotide for treating acquired hypothalamic obesity, showing potential as standard care options.
How can I contact Rhythm Pharmaceuticals?
For further inquiries, individuals can reach out by contacting David Connolly at Rhythm Pharmaceuticals through the provided phone number or email.
